Evidence map›Paper›PMID 21892751›Full record

ArticleVirchows Archiv : an international journal of pathology2011

The role of tumor hypoxia in MUC1-positive breast carcinomas.

Juliana Silva Zanetti, Danilo Fiqueredo Soave, João Paulo Oliveira-Costa, Giórgia Gobbi da Silveira, Leandra Náira Zambelli Ramalho, Sérgio Britto Garcia, Sérgio Zucoloto, Alfredo Ribeiro-Silva

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Use of Radiomics in Characterizing Tumor Hypoxia.International journal of molecular sciences · 2025
    Review
  3. The multifaceted role of MUC1 in tumor therapy resistance.Clinical and experimental medicine · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Peptide-Based Treatment: A Promising Cancer Therapy.Journal of immunology research · 2015
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Juliana Silva ZanettiDepartment of Pathology, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes 3900, Ribeirão Preto, SP, 14049-900, Brazil.
Danilo Fiqueredo Soave
João Paulo Oliveira-Costa
Giórgia Gobbi da Silveira
Leandra Náira Zambelli Ramalho
Sérgio Britto Garcia
Sérgio Zucoloto
Alfredo Ribeiro-Silva
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucin 1 (MUC1) is a glycoprotein that is expressed on apical cell membranes in a variety of normal tissues. MUC1 is involved in cell signaling, inhibition of cell-cell and cell matrix adhesion, apoptosis, proliferation, and transcription. Hypoxia is an important factor that promotes cancer metastasis and stimulates angiogenesis and tumor progression. Hypoxia inducible factor 1 (HIF-1α) and carbonic anhydrase IX (CAIX) are two molecules that are involved in this process. The role of hypoxia in MUC1+ invasive ductal breast carcinomas is not well established. In this study, the expression of MUC1 was correlated with the hypoxia-associated markers HIF-1α and CAIX, as well as several immunohistochemical markers and clinicopathologic features of prognostic significance in 243 invasive ductal carcinomas. MUC1 was overexpressed in 37.0% of patients and correlated with the expression of estrogen receptor (p = 0.0001), progesterone receptor (p = 0.0001), HIF-1α (p = 0.006), VEGF (p = 0.024), and p53 (p = 0.025). In breast cancer, MUC1 expression has been associated with increased degradation of inhibitor of NF-κB (IκBα), driving NF-κB to the nucleus and blocking apoptosis and promoting cell survival. We analyzed NF-κB expression in MUC1+ breast carcinoma and found a very significant relationship between these proteins (p = 0.0001). Our findings indicate that MUC1 may play a role in the regulation of hormone receptors by increasing the inactivation of p53 and targeting NF-κB to the nucleus. Our data also support the notion that activation of HIF-1α in MUC1+ breast carcinomas may modulate VEGF expression, allowing a metabolic adaptation to hypoxia.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCell HypoxiaDisease-Free SurvivalFemaleHumansHypoxia-Inducible Factor 1, alpha SubunitImmunohistochemistryIn Situ Nick-End LabelingKaplan-Meier EstimateMiddle AgedMucin-1Biomarkers, TumorHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitMUC1 protein, humanMucin-1NF-kappa BReceptors, EstrogenReceptors, ProgesteroneTumor Suppressor Protein p53Vascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID21892751
OpenAlexW2075869925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.